Spyre Therapeutics, Inc. SYRE Income Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $171.65M+5.4% | $162.79M+81.9% | $89.5M+52.8% | $58.58M+2.6% | ||
| $47.91M+4.7% | $45.78M+14.6% | $39.95M+40.0% | $28.53M+4.4% | ||
| $209.56M+0.5% | $208.57M-14.2% | $243.19M+179% | $87.11M+3.2% | ||
| -$209.56M-0.5% | -$208.57M+13.9% | -$242.3M-186% | -$84.78M-29.1% | ||
| $59.7M+9,867% | $599K+101% | -$96.51M-12,104% | $804K— | ||
| -$155.22M+25.4% | -$207.97M+38.6% | -$338.82M-303% | -$83.98M-27.9% | ||
| -$15K-129% | $51K+296% | -$26K— | —— | ||
| -$155.2M+25.4% | -$208.02M+38.6% | -$338.79M-304% | -$83.82M-27.4% | ||
| -$1.98+37.7% | -$3.18— | —— | -$10.17+59.4% | ||
| -$209.56M-0.5% | -$208.57M— | —— | -$83.21M-29.9% | ||
| -$209.56M-0.5% | -$208.57M+13.9% | -$242.3M-186% | -$84.78M-29.1% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Is Spyre Therapeutics, Inc. profitable?
- Spyre Therapeutics, Inc. is not currently profitable: it reported a net loss of $179.4M over the trailing twelve months, a -52939.7% net margin.
- What is Spyre Therapeutics, Inc.'s earnings per share?
- Spyre Therapeutics, Inc.'s diluted EPS over the trailing twelve months is $-2.12.
- Where does Spyre Therapeutics, Inc.'s income statement data come from?
- Every line is extracted from Spyre Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.